Short answer. Irritability was common in one study that followed 50 mildly depressed women in perimenopause weekly for eight weeks. Of them, 82.0% reported moderate to severe irritability at least once (de Wit et al., 2021). For the same woman, how intense it felt varied widely from one week to the next. Depression accounted for at most about a fifth of the differences, which suggests low mood doesn’t fully explain irritability (de Wit et al., 2021).
Key facts
- The sample was 50 mildly depressed perimenopausal women, average age 48.4. Over eight weeks, 82.0% reported moderate to severe irritability at least once (de Wit et al., 2021).
- Depression severity had the strongest link to irritability, but it accounted for no more than 20.3% of the variance in irritability. Progesterone and follicle-stimulating hormone (FSH) weren’t linked to it (de Wit et al., 2021).
- Earlier work linked estradiol swings more to depressive symptoms, the opposite of the irritability finding here. The two studies measured estradiol swings in different ways, so they can’t be compared directly. In that other study, estradiol that swung more over 14 months predicted depressive symptoms at month 14, but only in women with more very stressful life events (Gordon et al., 2016).
One woman described it online: “…anger that lasted for hours (instead of 15 minutes). I felt out of control.”
How irritability was measured
The researchers’ word for it is irritability. De Wit and colleagues measured it with the hostility subscale (one section) of a symptom questionnaire, scored weekly. By that measure, most women in the sample had at least one week of moderate to severe irritability. How bad it was swung widely from week to week. The within-person coefficient of variation was 63.7% (a measure of how much one woman’s own scores swing), so on average it wasn’t a steady state (de Wit et al., 2021).
What went along with irritability
Factor | Direction of association with irritability |
Greater depression severity | More irritability |
Younger age | More irritability |
Less variable estradiol (week-to-week) | More irritability |
More frequent hot flushes and night sweats (vasomotor symptoms) | More irritability |
Progesterone or FSH levels | No association found |
The researchers say irritability can be told apart from depressive symptoms in perimenopausal women and may be tied to different estradiol patterns (de Wit et al., 2021). Earlier work found the opposite direction for depressive symptoms: estradiol that swung more went with more of them.
Estradiol, stress and mood in the Gordon study
Gordon and colleagues followed 52 women who had no depression at the start and were in the placebo group of a clinical trial. Estradiol variability predicted depressive symptoms at month 14 only in women who had more very stressful life events. It also predicted feelings of rejection in response to a laboratory stressor (Gordon et al., 2016). Women also rated anger during the lab stressor, but the abstract reports the estradiol links only for rejection and depressive symptoms. So the study speaks to hormones and stress sensitivity in general, not to rage.
Noticing your own pattern
The studies describe links and didn’t test treatments, so they can’t say what will help you. Some women find it useful to note how their irritability changes from week to week, since it fluctuates widely, and how it lines up with sleep, hot flushes and their general mood. A written record can give a doctor something to work with.
The 2026 hormone therapy label change and mood
On February 12, 2026, the US Food and Drug Administration (FDA) approved new labels for the first six menopausal hormone therapy products. The FDA took three risk statements out of the boxed warning (the most prominent warning on a drug label): cardiovascular disease, breast cancer, and probable dementia. In total, 29 companies have sent in proposed label changes (FDA, 2026).
The two studies above weren’t about hormone therapy, so the label change doesn’t settle anything about irritability. One randomized trial (a study where women are assigned by chance to treatment or placebo) looked at mood. It followed 172 women aged 45 to 60 who had no depressive symptoms at the start. Over 12 months, 32.3% of the women on placebo developed clinically significant depressive symptoms, compared with 17.3% of the women using an estradiol patch plus periodic progesterone (Gordon et al., 2018). The mood benefit was clearest in women early in the menopause transition. That trial measured depressive symptoms, not irritability. Whether hormone therapy suits you depends on your health history, so that decision belongs to you and a doctor.
What the research can’t tell us
- The 82% figure comes from 50 women who already had mild depression, so it can’t be applied to all women in perimenopause (de Wit et al., 2021).
- The irritability study was observational: researchers followed women and didn’t assign treatments, so it can’t show that hormone patterns cause irritability.
- In the Gordon study, the estradiol links reported were for depressive symptoms and feelings of rejection, not anger. The study had 52 participants (Gordon et al., 2016).
- Neither of these two studies tested treatments, including hormone therapy.
When should you talk to a professional?
It’s worth seeing a doctor if irritability or low mood is affecting your relationships or work, comes with persistent sadness, or leaves you feeling out of control more often than not. Hot flushes, sleep disruption, and mood changes during perimenopause are worth discussing together, because a clinician can look at the whole picture. If you have thoughts of harming yourself or someone else, contact emergency services right away.
Where Soula can fit in
Soula is an AI companion, not a doctor, so it can’t tell you what’s behind your irritability. Its cycle tracking shows where a rough week falls in your month, and the check-ins and AI-assistant chat give you a place to talk it through. If the pattern keeps going, Soula encourages you to bring what you notice to a doctor.
FAQ
Is my irritability really from perimenopause?
This study can’t tell. All 50 women already had mild depression, and none of them was compared with women outside perimenopause (de Wit et al., 2021).
Can hormones explain irritability?
Estradiol patterns were linked to irritability and to depressive symptoms, in different directions. Both analyses observed hormones and mood and did not test a treatment (de Wit et al., 2021; Gordon et al., 2016).
Did the FDA change anything about hormone therapy in 2026?
In February 202,6 the FDA approved new labels for the first six products and removed three risk statements from the boxed warning. That doesn’t settle anything about irritability, and the one mood trial measured depressive symptoms, so it’s a question for your doctor (FDA, 2026; Gordon et al., 2018).
Is irritability a symptom of perimenopause?
It was common in the one study covered here: 82.0% of 50 mildly depressed women reported moderate to severe irritability at least once over eight weeks (de Wit et al., 2021).
Is perimenopause rage the same as depression?
Not entirely. Depression went along with irritability, yet it left most of the variation unexplained, and the estradiol pattern ran the opposite way from the one seen for depressive symptoms (de Wit et al., 2021; Gordon et al., 2016).
Do hormones cause perimenopausal anger?
Not from this research. It describes estradiol patterns alongside irritability, and no one was given a hormone treatment to see what changed.
Which hormones were linked to irritability?
Estradiol that varied less from week to week was linked to more irritability. Progesterone and FSH weren’t linked to it (de Wit et al., 2021).
References
- de Wit, A. E., Giltay, E. J., de Boer, M. K., et al. (2021). Predictors of irritability symptoms in mildly depressed perimenopausal women. Psychoneuroendocrinology, 126, 105128. https://doi.org/10.1016/j.psyneuen.2021.105128
- Gordon, J. L., Rubinow, D. R., Eisenlohr-Moul, T. A., et al. (2016). Estradiol variability, stressful life events, and the emergence of depressive symptomatology during the menopausal transition. Menopause, 23(3), 257–266. https://doi.org/10.1097/gme.0000000000000528
- US Food and Drug Administration. (2026, February 12). FDA approves labeling changes to menopausal hormone therapy products [Press announcement]. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products
- Gordon, J. L., Rubinow, D. R., Eisenlohr-Moul, T. A., Xia, K., Schmidt, P. J., & Girdler, S. S. (2018). Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: A randomized clinical trial. JAMA Psychiatry, 75(2), 149–157. https://doi.org/10.1001/jamapsychiatry.2017.3998
